IGC Pharma

IGC Pharma Current Liabilities

The Current Liabilities of IGC Pharma (IGC) as of Nov 12, 2026 is 2.87 M USD. In the previous year, Current Liabilities was 2.51 M USD — a change of 14.28% (higher).

Current Liabilities

2.87 MUSD

YoY

14.28%

Last updated:

Current Liabilities of IGC Pharma is 2026 2.87 M USD. Current Liabilities of IGC Pharma was 2025 2.51 M USD. It decreases by 14.28% higher compared to the previous year.

The IGC Pharma Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2019
964,000.00 USD
Jan 1, 2020
2.51 M USD
Jan 1, 2021
3.61 M USD
Jan 1, 2022
3.62 M USD
Jan 1, 2023
2.65 M USD
Jan 1, 2024
3.28 M USD
Jan 1, 2025
2.51 M USD
Jan 1, 2026
2.87 M USD
The IGC Pharma Current Liabilities history
YEARCurrent LiabilitiesYoY
2.87 MUSD+14.28%
2.51 MUSD-23.42%
3.28 MUSD+23.98%
2.65 MUSD-26.87%
3.62 MUSD+0.36%
3.61 MUSD+43.97%
2.51 MUSD+159.96%
964,000.00USD-58.91%
2.35 MUSD-42.98%
4.11 MUSD+2.36%
4.02 MUSD+19.69%
3.36 MUSD+129.89%
1.46 MUSD-19.31%
1.81 MUSD-56.51%
4.16 MUSD-37.32%
6.64 MUSD-17.49%
8.05 MUSD+17.19%
6.87 MUSD-100.71%
-970.93 MUSD-20,995.47%
4.65 MUSD+44.51%
3.22 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IGC Pharma Stock analysis

What does IGC Pharma do? India Globalization Capital Inc. (IGC) is a Maryland-based company that focuses on the development, marketing, and sale of natural supplements, novel cannabis formulations, food and beverages, and the manufacturing of medical devices. IGC was established in 2005 and initially operated as a construction company in India. However, over the years, the company has evolved into a diversified company based in Maryland due to its innovative products and services. One of IGC's most well-known divisions is IGC Pharma, which focuses on cannabis-based medical formulations and medical devices. IGC holds patent applications for certain cannabis-based products and was one of the first companies to explore the use of cannabis as a potential treatment for Alzheimer's patients. In collaboration with the Institute for Medicine and the Origins of Infancy at the University of Maryland, IGC developed a novel THC-based medication for the treatment of spasms, pain, and other symptoms in multiple sclerosis patients. IGC has also developed the "Hyalolex" product, which is made from specific cannabinoids such as CBD. This preparation is available in Germany under the trade name "Cannabidiol Hexal." Hyalolex is available as a dietary supplement and has been proven effective in improving memory performance, attention, and cognitive abilities in Alzheimer's patients. IGC also operates the IGC Nutraceuticals division, which focuses on the manufacturing and marketing of high-quality natural products. These include vitamins, minerals, dietary supplements, and natural herbal supplements that promote physical and mental well-being and support healthy bodily processes. Some of IGC Nutraceuticals' products include Saffron for Depression Relief, the calcium and magnesium formulation, and Bharat Diagnostics. IGC will continue to invest in various fields, including cannabis-based pain relief, dementia treatments, electrochemical energy storage, and the manufacturing of devices that utilize natural resources such as coal and ore. Overall, IGC has become a diversified company that focuses on a variety of industries. IGC has been a pioneer in the cannabis industry and has gained a good reputation through innovative formulations and patents. By expanding into new industries and investing in new technologies, IGC will continue to stay at the forefront of innovation and strengthen its position as one of the emerging development companies in today's economy. IGC Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IGC Pharma stock

Current Liabilities of IGC Pharma is 2.87 M USD in 2026.

Current Liabilities of IGC Pharma changed from 2.51 M USD to 2.87 M USD, representing a 14.28% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities IGC Pharma since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's IGC Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — IGC Pharma

All Key Metrics — IGC Pharma